BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8749839)

  • 1. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
    Bond AJ; Curran HV; Bruce MS; O'Sullivan G; Shine P
    J Affect Disord; 1995 Dec; 35(3):117-23. PubMed ID: 8749839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 3. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
    O'Sullivan GH; Noshirvani H; Başoğlu M; Marks IM; Swinson R; Kuch K; Kirby M
    Br J Psychiatry; 1994 Jul; 165(1):79-86. PubMed ID: 7802851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
    Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O
    Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients.
    Kiliç C; Curran HV; Noshirvani H; Marks IM; Başoğlu M
    Psychol Med; 1999 Jan; 29(1):225-31. PubMed ID: 10077311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
    Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
    Moylan S; Staples J; Ward SA; Rogerson J; Stein DJ; Berk M
    J Clin Psychopharmacol; 2011 Oct; 31(5):647-52. PubMed ID: 21869686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 15-year follow-up study of patients with panic disorder.
    Andersch S; Hetta J
    Eur Psychiatry; 2003 Dec; 18(8):401-8. PubMed ID: 14680716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment.
    Curtis GC; Abelson JL; Gold PW
    Biol Psychiatry; 1997 Jan; 41(1):76-85. PubMed ID: 8988798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.
    Pyke RE; Greenberg HS
    J Clin Psychopharmacol; 1989 Feb; 9(1):15-21. PubMed ID: 2651489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy.
    Brambilla F; Bellodi L; Perna G
    Psychiatry Res; 1999 Dec; 89(1):21-7. PubMed ID: 10643874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to alprazolam and placebo in patients with panic disorder.
    Woodman CL; Noyes R; Ballenger JC; Lydiard RB; Sievers G; Mihalko D
    J Affect Disord; 1994 Jan; 30(1):5-13. PubMed ID: 8151049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of panic disorder.
    Cassano GB; Toni C; Musetti L
    Adv Biochem Psychopharmacol; 1992; 47():449-60. PubMed ID: 1509926
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation reactions to alprazolam in panic disorder.
    Pecknold JC
    J Psychiatr Res; 1993; 27 Suppl 1():155-70. PubMed ID: 8145176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
    Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.